Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • Mar 22, 2018

IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, March 22, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on March 19 and 21, 2018.

Reason for the notification	Upwards crossing followed by a downwards crossing of the 3%
	threshold further to the acquisition and disposal of shares –and thus
	voting rights- held as loan collateral
Persons subject to the	IBA SA, issuer
notification requirement
Persons that dispose of voting	Norges Bank
rights
Transaction date	16/03/2018	20/03/2018
Threshold that is crossed (in	3%	3%
%)	Upwards crossing further to	Downwards
	the acquisition of voting rights	crossing further to
		the disposal of
		voting rights
Denominator	29 962 246	29 962 246
Voting rights (number)	902 875	859 382
Voting rights (%)	3,01%	2,87%
Chain of control	Norges Bank is the central bank of Norway. As part of its central
	bank activities, Norges Bank manages Norway's foreign exchange
	reserves and is responsible for management of the Norwegian
	Government Pension Fund Global (GPFG). The formal responsibility
	for management of the GPFG is placed with the Ministry of Finance,
	but is delegated to Norges Bank. All investments are executed by
	Norges Bank acting as principal and all holdings are registered in the
	name of Norges Bank.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin Legal Counsel +32 10 203 924 Stephanie.bauwin@iba-group.com

Press release | 22/03/2018